400 people in SA with highly drug-resistant TB to get new three-drug regimen

400 people in SA with highly drug-resistant TB to get new three-drug regimen

Treating highly drug-resistant forms of tuberculosis can take anything from nine to 24 months and patients have to contend with various unpleasant, and sometimes dangerous, side effects. A new six-month regimen made up of just three drugs that will be offered to 400 patients in South Africa might offer a better solution for some. Tiyese Jeranji reports.

Read More

COVID-19: How vaccine registration will work in SA

COVID-19: How vaccine registration will work in SA

Before any COVID-19 vaccines can be made available in South Africa, they must be authorised by South Africa’s medicines regulator—the South African Health Products Regulatory Authority (SAHPRA). Catherine Tomlinson explores how SAHPRA is preparing to review and authorise the use of COVID-19 vaccines in the country and the different authorisation approaches they may use.

Read More

IN-DEPTH: The tangled web of medical device regulation in SA

IN-DEPTH: The tangled web of medical device regulation in SA

South Africa does not currently register medical devices. So what does it mean when the regulator announces that a new COVID-19 test or ventilator has been authorised? Catherine Tomlinson unpacks what is required to market a medical device in South Africa.

Read More

Do we need the law to provide for a regular clinical medical procedure such as abortion?

Do we need the law to provide for a regular clinical medical procedure such as abortion?

With abortion services now available through telemedicine and the increasing practice of self-managed abortion, Marion Stevens asks if abortion law still has any relevance given these practices.

Read More

Breakthrough hepatitis C medicines remain in regulatory limbo

Breakthrough hepatitis C medicines remain in regulatory limbo

Over the last decade the treatment of hepatitis C, a virus that can infect and damage the liver, has been revolutionised by a new class of medicines called direct acting antivirals. Catherine Tomlinson investigates the regulatory obstacles that are limiting access to these breakthrough medicines in South Africa.

Read More